{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li W"],"funding":["Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","Beijing Municipal Science and Technology Commission","Capital's Funds for Health Improvement and Research","National Key Research and Development Program of China"],"pagination":["709-718"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966215"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(2)"],"pubmed_abstract":["<h4>Aims</h4>Relationship between body mass index (BMI), frailty, and clinical adverse events remains unclear in patients with heart failure (HF) with preserved ejection fraction (HFpEF) in different patient populations. We aimed to compare the association of BMI, frailty, and clinical adverse events between a US cohort from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study and a Chinese cohort from the Heart Failure Registry of Patient Outcomes (HERO) study.<h4>Methods and results</h4>We used data of 1715 participants enrolled from America in the TOPCAT study and 1487 patients with HFpEF in the Chinese registry study, the HERO. We evaluated the relationship between BMI and frailty using multivariate restricted cubic spline logistic reg"],"journal":["ESC heart failure"],"pubmed_title":["Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction."],"pmcid":["PMC10966215"],"funding_grant_id":["D171100006817001","2022-2-2067","2020YFC2004803"],"pubmed_authors":["Li W","Liu X","Ma C","Zhang H","Dong J","Zheng S","Du X","Hua C","Jiang C","Wang Z","Lv Q"],"additional_accession":[]},"is_claimable":false,"name":"Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction.","description":"<h4>Aims</h4>Relationship between body mass index (BMI), frailty, and clinical adverse events remains unclear in patients with heart failure (HF) with preserved ejection fraction (HFpEF) in different patient populations. We aimed to compare the association of BMI, frailty, and clinical adverse events between a US cohort from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study and a Chinese cohort from the Heart Failure Registry of Patient Outcomes (HERO) study.<h4>Methods and results</h4>We used data of 1715 participants enrolled from America in the TOPCAT study and 1487 patients with HFpEF in the Chinese registry study, the HERO. We evaluated the relationship between BMI and frailty using multivariate restricted cubic spline logistic reg","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-04-04T12:24:48.225Z","creation":"2025-04-04T12:24:48.225Z"},"accession":"S-EPMC10966215","cross_references":{"pubmed":["38131256"],"doi":["10.1002/ehf2.14595"]}}